Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Previous studies suggest that individuals who are homozygous-null at the GSTM1 or GSTT1 locus may have an increased risk of environmentally related cancers and drug-induced hepatotoxicity.
|
30471640 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
|
24903797 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients.
|
25525805 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
|
23232001 |
2013 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.
|
22335459 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury.
|
22845549 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Homozygosity for GSTM1 null and/or GSTT1 null alleles also seems to be a risk factor for DILI, with associations described independently for several drugs.
|
20415545 |
2010 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Conclusive evidence for association with DILI risk has been obtained for non-mutated CYP2E1, slow NAT2 and slow GSTM1 genotypes.
|
20214588 |
2009 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
No significant association was observed between the GSTM1 homozygous null polymorphism and antituberculosis drug-induced hepatotoxicity (OR 0.73, 95% CI 0.31-1.73, P=0.48).
|
18397238 |
2008 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
The double-null genotype for GSTT1 and GSTM1 might play a role in determining the susceptibility to develop DILI, as a general mechanism that occurs regardless of the type of drug involved, and predominantly in women.
|
18666253 |
2008 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The double-null genotype for GSTT1 and GSTM1 might play a role in determining the susceptibility to develop DILI, as a general mechanism that occurs regardless of the type of drug involved, and predominantly in women.
|
18666253 |
2008 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity.
|
17465707 |
2007 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
In addition, subjects carrying GSTM1 null genotype had increased risk of anti-tuberculosis DILI (adjusted OR: 2.23, 95% C.I.: 1.07-4.67, P=0.03).
|
17400324 |
2007 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation.
|
11595069 |
2001 |